Intellia Therapeutics, Inc. cash flow to debt ratio of -373.82% indicates that the company cannot generate enough cash to cover its debt over time. This level indicates weak financial health.

Intellia Therapeutics, Inc.'s free cash flow has increased -0.00% from $-354.66M last year to $-354.66M, signaling increasing performance

Intellia Therapeutics, Inc.'s debt to equity ratio is 0.13, which means that the company's assets are healthy financed, signaling financial stability. READ MORE: A ratio under 0.60 means the company finances its assets with own equity, signaling financial stability and good management.

Intellia Therapeutics, Inc.'s debt has decreased relative to shareholder equity from 0.24 last year to 0.13 today, signaling strengthened financials

Intellia Therapeutics, Inc. has negative EBITDA, making leverage ratio unreliable

Intellia Therapeutics, Inc. earns at least as much interest as it pays. Interest obligations are fully covered.

Intellia Therapeutics, Inc.'s profit margin has increased (-33.42%) in the last year from -896.77% to -597.04%, signaling increasing performance

Intellia Therapeutics, Inc.'s short-term assets of $527.71M exceed its short-term liabilities of $103.88M

Intellia Therapeutics, Inc.'s return on assets of 0.00% is lower than the 5.00% threshold, indicating inefficient asset utilization

Intellia Therapeutics, Inc.'s return on equity of -57.27%, is lower than 15.00%, indicating bad performance

Intellia Therapeutics, Inc.'s operating cash flow is lower than its net income, indicating that earnings may not be fully backed by cash generation

Intellia Therapeutics, Inc. had positive net income in only 0.00 out of 5 years, indicating unstable earnings

Intellia Therapeutics, Inc. has negative free cash flow, indicating the company is burning cash rather than generating it

Intellia Therapeutics, Inc. has negative free cash flow, indicating cash burn

Intellia Therapeutics, Inc.'s yearly earnings has increased -20.49% since last year from $-519.02M to $-412.69M, signaling increasing performance

Intellia Therapeutics, Inc.'s yearly revenue has increased 16.92% since last year from $57.88M to $67.67M, signaling increasing performance

ROIC -59.98% (Source: FMP key-metrics). Below the 5% partial-credit threshold. Score: 0 of 2. The 5% and 10% cutoffs anchor to typical US weighted-average cost of capital. Below 5% indicates the company is not generating returns above its likely cost of capital under this definition of invested capital. Invested capital here includes equity, non-current liabilities (pension obligations, deferred taxes, lease obligations), and short-term debt. Cash is not subtracted. Companies with substantial float, lease portfolios, or cash holdings will score lower under this definition than under narrower operating-capital definitions. See methodology.

Intellia Therapeutics, Inc.'s 3-year revenue CAGR of 9.09% is positive, indicating growing revenue over the past 3 years

Intellia Therapeutics, Inc. had revenue growth in 3.00 out of 5 years, indicating consistent revenue performance

Intellia Therapeutics, Inc. had positive ROE in only 0.00 out of 5 years, indicating inconsistent returns on equity

Intellia Therapeutics, Inc. has insufficient data to evaluate this check.

Intellia Therapeutics, Inc. has negative trailing-twelve-month earnings; this ratio is not meaningful and the check fails

Intellia Therapeutics, Inc. is overvalued relative to its fair value price of 0.00 based on EBITDA multiple model

Intellia Therapeutics, Inc. has negative or missing EBITDA, making EV/EBITDA ratio unreliable

Intellia Therapeutics, Inc. has insufficient data to evaluate this check.

Intellia Therapeutics, Inc. has negative trailing-twelve-month earnings; this ratio is not meaningful and the check fails

Intellia Therapeutics, Inc. has a price-to-book ratio of 3.18x, which is below the 5.00x threshold, indicating reasonable valuation relative to its book value

Intellia Therapeutics, Inc. has a price-to-sales ratio of 28.32x, which exceeds the 8.00x threshold, indicating the stock may be overvalued relative to its revenue